Stephanie Korn

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

Ian Pavord, Stephanie Korn, Peter Howarth et al. · The Lancet · 2012 · 2.2K citations

Life Sciences, Internal Medicine, Pharmacotherapy +14

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

J. Mark FitzGerald, Eugene R. Bleecker, Parameswaran Nair et al. · The Lancet · 2016 · 1.4K citations

Pharmacy, Immunology, Pharmacology +17

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

Mario Castro, James Zangrilli, Michael E. Wechsler et al. · The Lancet Respiratory Medicine · 2015 · 1.2K citations

Life Sciences, Immunology, Pharmacotherapy +11

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease

Ian Pavord, Pascal Chanez, Gerard J. Criner et al. · New England Journal of Medicine · 2017 · 591 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial

Christopher E. Brightling, Pascal Chanez, Richard Leigh et al. · The Lancet Respiratory Medicine · 2015 · 366 citations

Medicine, Clinical Sciences, Immunology +8